{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wang Y"],"funding":["Tsinghua University","Center for Life Sciences","Beijing Frontier Research Center for Biological Structure, Tsinghua University","National Natural Science Foundation of China","Beijing Natural Science Foundation"],"pagination":["111038"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12907715"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["302(2)"],"pubmed_abstract":["The cGAS-STING signaling pathway is a crucial innate immune pathway that senses cytosolic DNA. Pharmacological activation of the cGAS-STING pathway might be a promising strategy for cancer immunotherapy. Here, we report that the cGAS-STING pathway is a new target of telatinib, an orally available vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor that has been investigated in clinical trials. In this study, we demonstrated that telatinib induced innate immune responses in a STING-dependent manner. In addition, we determined the crystal structure of STING bound to a telatinib analog, revealing the molecular interactions underlying STING activation. Moreover, we showed that telatinib-mediated STING activation contributed to the antitumor effects in tumor-bearing mouse models. I"],"journal":["The Journal of biological chemistry"],"pubmed_title":["Activation of stimulator of interferon genes (STING) and inhibition of vascular endothelial growth factor receptor (VEGFR) by telatinib induce antitumor activity."],"pmcid":["PMC12907715"],"funding_grant_id":["32070875","82241074","22101036","Z220018"],"pubmed_authors":["Yang J","Chen K","Zhang Z","Liu P","Han J","Wang Y","Zhang C","Hou Y","Cheng Y","Mou L","Fan S","Dai Y"],"additional_accession":[]},"is_claimable":false,"name":"Activation of stimulator of interferon genes (STING) and inhibition of vascular endothelial growth factor receptor (VEGFR) by telatinib induce antitumor activity.","description":"The cGAS-STING signaling pathway is a crucial innate immune pathway that senses cytosolic DNA. Pharmacological activation of the cGAS-STING pathway might be a promising strategy for cancer immunotherapy. Here, we report that the cGAS-STING pathway is a new target of telatinib, an orally available vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor that has been investigated in clinical trials. In this study, we demonstrated that telatinib induced innate immune responses in a STING-dependent manner. In addition, we determined the crystal structure of STING bound to a telatinib analog, revealing the molecular interactions underlying STING activation. Moreover, we showed that telatinib-mediated STING activation contributed to the antitumor effects in tumor-bearing mouse models. I","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-07-16T05:02:06.715Z","creation":"2026-07-09T10:36:31.785Z"},"accession":"S-EPMC12907715","cross_references":{"pubmed":["41380972"],"doi":["10.1016/j.jbc.2025.111038"]}}